Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Grove

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1997
Neurotoxicity of CI-980, a novel mitotic inhibitorC A Meyers, A P Kudelka, C A Conrad, et al.
Acta Psychiatrica Scandinavica|December 1, 1986
Immigration and major affective disorderW Grove, P J Clayton, J Endicott, et al.
American Journal of Clinical Oncology|December 10, 1997
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicityR Pazdur, C Meyers, E Diaz-Canton, et al.
Investigational New Drugs|November 1, 1990
3-Deazaguanine: report of a phase I trial and drug-related cardiac toxicityK Margolin, J Doroshow, L Leong, et al.
Cancer Chemotherapy and Pharmacology|November 7, 1999
A phase II trial of CI-958 in patients with hormone-refractory prostate cancerP V Woolley, F S Freiha, D C Smith, et al.
Neuromodulation : Journal of the International Neuromodulation Society|December 14, 2011
Continuous Intrathecal Infusion of Ziconotide for Treatment of Chronic Malignant and Nonmalignant Pain Over 12 Months: A Prospective, Open-label StudyDavid J Ellis, Sanjeeva Dissanayake, Dawn McGuire, et al.
Cancer Research|November 15, 1988
Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921)J R Hardy, V J Harvey, J W Paxton, et al.
Journal of Personality Disorders|May 6, 1999
The Iowa Personality Disorder Screen: development and preliminary validation of a brief screening interviewD R Langbehn, B M Pfohl, S Reynolds, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2006
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter studyD A Richards, K A Boehm, D M Waterhouse, et al.
Scientific Reports|November 15, 2022
Low net carbonate accretion characterizes Florida's coral reefJohn T Morris, Ian C Enochs, Nicole Besemer, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1997
Neurotoxicity of CI-980, a novel mitotic inhibitorC A Meyers, A P Kudelka, C A Conrad, et al.
Acta Psychiatrica Scandinavica|December 1, 1986
Immigration and major affective disorderW Grove, P J Clayton, J Endicott, et al.
American Journal of Clinical Oncology|December 10, 1997
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicityR Pazdur, C Meyers, E Diaz-Canton, et al.
Investigational New Drugs|November 1, 1990
3-Deazaguanine: report of a phase I trial and drug-related cardiac toxicityK Margolin, J Doroshow, L Leong, et al.
Cancer Chemotherapy and Pharmacology|November 7, 1999
A phase II trial of CI-958 in patients with hormone-refractory prostate cancerP V Woolley, F S Freiha, D C Smith, et al.
Neuromodulation : Journal of the International Neuromodulation Society|December 14, 2011
Continuous Intrathecal Infusion of Ziconotide for Treatment of Chronic Malignant and Nonmalignant Pain Over 12 Months: A Prospective, Open-label StudyDavid J Ellis, Sanjeeva Dissanayake, Dawn McGuire, et al.
Cancer Research|November 15, 1988
Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921)J R Hardy, V J Harvey, J W Paxton, et al.
Journal of Personality Disorders|May 6, 1999
The Iowa Personality Disorder Screen: development and preliminary validation of a brief screening interviewD R Langbehn, B M Pfohl, S Reynolds, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2006
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter studyD A Richards, K A Boehm, D M Waterhouse, et al.
Scientific Reports|November 15, 2022
Low net carbonate accretion characterizes Florida's coral reefJohn T Morris, Ian C Enochs, Nicole Besemer, et al.
Pageof 4